PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the relationship between lymph node metastasis and the clinicopathologic features of differentiated thyroid carcinoma (DTC) patients with thyroglobulin antibody (TgAb) positive and negative.
UNASSIGNED: A total of 443 patients with DTC were included in this study. Clinicopathological data of the patients were collected, including tumor size, clinical stage, calcification, Hashimoto\'s thyroiditis, extra-membrane infiltration, BRAF V600E mutation status, and thyroid-related hormone and antibody levels. The relationship between of lymph node metastasis and clinicopathologic features was analyzed.
UNASSIGNED: There were 227(51.2%) TgAb negative and 216(48.8%) TgAb positive DTC patients. Compared with patients without lymph node metastasis, DTC patients with lymph node metastasis had a higher proportion of patients with <55 years of age, maximum tumor diameter >1cm, calcification, BRAF V600E mutation, and TgAb positive. Multivariate regression logistic analysis showed that <55 years old (odds ratio (OR): 2.744, 95% CI: 1.665-4.522, P<0.001), maximum tumor diameter >1cm (OR: 2.163, 95% CI: 1.431-3.271, P<0.001), BRAF V600E mutation (OR: 2.489, 95% CI: 1.397-4.434, P=0.002), and TgAb positive (OR: 1.540, 95% CI: 1.020-2.326, P=0.040) were risk factors for lymph node metastasis. Maximum tumor diameter >1cm and BRAF V600E increased the risk by more than one fold for lymph node metastasis in TgAb-negative and TgAb-positive DTC patients.
UNASSIGNED: Younger age (<55 years old), maximum tumor diameter >1cm, BRAF V600E mutation, and TgAb positive were independent risk factors for lymph node metastasis in DTC. And maximum tumor diameter >1cm and BRAF V600E mutation were risk factors for lymph node metastasis both in TgAb positive and negative DTC patients.
UNASSIGNED: A total of 443 patients with DTC were included in this study. Clinicopathological data of the patients were collected, including tumor size, clinical stage, calcification, Hashimoto\'s thyroiditis, extra-membrane infiltration, BRAF V600E mutation status, and thyroid-related hormone and antibody levels. The relationship between of lymph node metastasis and clinicopathologic features was analyzed.
UNASSIGNED: There were 227(51.2%) TgAb negative and 216(48.8%) TgAb positive DTC patients. Compared with patients without lymph node metastasis, DTC patients with lymph node metastasis had a higher proportion of patients with <55 years of age, maximum tumor diameter >1cm, calcification, BRAF V600E mutation, and TgAb positive. Multivariate regression logistic analysis showed that <55 years old (odds ratio (OR): 2.744, 95% CI: 1.665-4.522, P<0.001), maximum tumor diameter >1cm (OR: 2.163, 95% CI: 1.431-3.271, P<0.001), BRAF V600E mutation (OR: 2.489, 95% CI: 1.397-4.434, P=0.002), and TgAb positive (OR: 1.540, 95% CI: 1.020-2.326, P=0.040) were risk factors for lymph node metastasis. Maximum tumor diameter >1cm and BRAF V600E increased the risk by more than one fold for lymph node metastasis in TgAb-negative and TgAb-positive DTC patients.
UNASSIGNED: Younger age (<55 years old), maximum tumor diameter >1cm, BRAF V600E mutation, and TgAb positive were independent risk factors for lymph node metastasis in DTC. And maximum tumor diameter >1cm and BRAF V600E mutation were risk factors for lymph node metastasis both in TgAb positive and negative DTC patients.
摘要：
■探讨甲状腺球蛋白抗体(TgAb)阳性和阴性的分化型甲状腺癌(DTC)患者淋巴结转移与临床病理特征的关系。
■本研究共纳入443例DTC患者。收集患者的临床病理资料,包括肿瘤大小,临床分期,钙化,桥本甲状腺炎,膜外渗透,BRAFV600E突变状态,甲状腺相关激素和抗体水平。分析淋巴结转移与临床病理特征的关系。
■有227例(51.2%)TgAb阴性和216例(48.8%)TgAb阳性DTC患者。与无淋巴结转移的患者相比，有淋巴结转移的DTC患者在年龄<55岁的患者中比例较高,肿瘤最大直径>1cm,钙化,BRAFV600E突变,和TgAb阳性。多因素logistic回归分析显示<55岁(比值比(OR):2.744,95%CI:1.665~4.522,P<0.001),肿瘤最大直径>1cm(OR:2.163,95%CI:1.431-3.271,P<0.001),BRAFV600E突变(OR:2.489,95%CI:1.397-4.434,P=0.002),TgAb阳性(OR:1.540,95%CI:1.020~2.326,P=0.040)是淋巴结转移的危险因素。最大肿瘤直径>1cm和BRAFV600E使TgAb阴性和TgAb阳性DTC患者的淋巴结转移风险增加1倍以上。
■年龄较小（<55岁），肿瘤最大直径>1cm,BRAFV600E突变,TgAb阳性是DTC淋巴结转移的独立危险因素。最大肿瘤直径>1cm和BRAFV600E突变是TgAb阳性和阴性DTC患者淋巴结转移的危险因素。
■本研究共纳入443例DTC患者。收集患者的临床病理资料,包括肿瘤大小,临床分期,钙化,桥本甲状腺炎,膜外渗透,BRAFV600E突变状态,甲状腺相关激素和抗体水平。分析淋巴结转移与临床病理特征的关系。
■有227例(51.2%)TgAb阴性和216例(48.8%)TgAb阳性DTC患者。与无淋巴结转移的患者相比，有淋巴结转移的DTC患者在年龄<55岁的患者中比例较高,肿瘤最大直径>1cm,钙化,BRAFV600E突变,和TgAb阳性。多因素logistic回归分析显示<55岁(比值比(OR):2.744,95%CI:1.665~4.522,P<0.001),肿瘤最大直径>1cm(OR:2.163,95%CI:1.431-3.271,P<0.001),BRAFV600E突变(OR:2.489,95%CI:1.397-4.434,P=0.002),TgAb阳性(OR:1.540,95%CI:1.020~2.326,P=0.040)是淋巴结转移的危险因素。最大肿瘤直径>1cm和BRAFV600E使TgAb阴性和TgAb阳性DTC患者的淋巴结转移风险增加1倍以上。
■年龄较小（<55岁），肿瘤最大直径>1cm,BRAFV600E突变,TgAb阳性是DTC淋巴结转移的独立危险因素。最大肿瘤直径>1cm和BRAFV600E突变是TgAb阳性和阴性DTC患者淋巴结转移的危险因素。
